SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis

There is a large and growing burden of diabetes globally. In 2013, 382 million people had diabetes and this number has been projected to increase to 592 million by 2035 [1]. With increasing life expectancy and prevalence of type 2 diabetes, complications and deaths attributable to diabetes will also increase, especially if there is no concomitant improvement in the health system for its early management [1]. Chronic kidney disease (CKD) is a common complication in people with type 2 diabetes [2] and may in some cases progress to end-stage renal disease, which requires dialysis and/or kidney transplant which are associated with high healthcare costs [3 –5].

Source: Primary Care Diabetes - February 23, 2018 Category: Primary Care Authors: Samuel Seidu, Setor K. Kunutsor, Xavier Cos, Syed Gillani, Kamlesh Khunti, For and on behalf of Primary Care Diabetes Europe Tags: Original research Source Type: research